Related Experiment Video

Updated: Aug 2, 2026

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents

K Bilello1, S Schultz, C Powell

  • 1Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
|January 1, 1994
PubMed

Insights

Diaspirin crosslinked hemoglobin (DCLHb) increases blood pressure. This study found that common antihypertensive drugs effectively controlled the pressor effect of DCLHb in rats.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology

Background:

  • Diaspirin crosslinked hemoglobin (DCLHb) is a blood substitute that can elevate mean arterial pressure (MAP).
  • Managing the pressor effects of DCLHb is crucial for its clinical application.

Purpose of the Study:

  • To investigate the efficacy of common antihypertensive agents in controlling the pressor effect of DCLHb.
  • To assess the impact of these agents on heart rate (HR) in conjunction with MAP control.

Main Methods:

  • Awake rats received an intravenous injection of DCLHb (280 mg/kg).
  • Subsequently, rats were treated with prazosin, nitroglycerine (NTG), nicardipine, or labetalol.
  • Mean arterial pressure (MAP) and heart rate (HR) were monitored throughout the experiment.

Main Results:

  • All tested antihypertensive agents (prazosin, NTG, nicardipine, labetalol) promptly restored elevated MAP to baseline levels.
  • Prazosin and NTG normalized HR, while nicardipine and labetalol resulted in persistent bradycardia.
  • The findings indicate that DCLHb-induced hypertension is manageable with various drug classes.

Conclusions:

  • The pressor effect of Diaspirin crosslinked hemoglobin can be effectively managed using widely available antihypertensive medications.
  • Different classes of antihypertensives exhibit varying effects on heart rate when counteracting DCLHb-induced hypertension.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...